Advances in early breast cancer risk profiling: from histopathology to molecular technologies

C Pescia, E Guerini-Rocco, G Viale, N Fusco - Cancers, 2023 - mdpi.com
Simple Summary Risk stratification for early breast cancer (BC) is extremely relevant for
tailoring clinical decisions but challenging due to the absence of comprehensive guidelines …

[HTML][HTML] Think “HER2” different: Integrative diagnostic approaches for HER2-low breast cancer

C Marchiò, C Criscitiello, C Scatena, A Santinelli… - Pathologica, 2023 - ncbi.nlm.nih.gov
This work explores the complex field of HER2 testing in the HER2-low breast cancer era,
with a focus on methodological aspects. We aim to propose clear positions to scientific …

18F-FES and 18F-FDG PET/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4/6 kinase inhibitors with …

C Liu, G Ma, J Zhang, J Cheng, Z Yang… - Annals of Nuclear …, 2023 - Springer
Objective The aim of this study was to investigate the potential value of dual tracers 18F-
FDG and 18F-FES PET/CT in predicting response to Cyclin-Dependent 4/6 Kinase (CDK4/6) …